The Tufts Clinical and Translational Science Institute has published a comprehensive resource on broadly engaged team science, which aims to include stakeholders in the research process. The book features perspectives and best practices from over 60 experts to inspire researchers and stakeholders to build diverse, inclusive teams.
A clinical trial of niclosamide in COVID-19 patients found signals of benefit warranting further study. The medication showed potential in reducing contagiousness and symptoms, particularly in higher-risk populations.
The study will recruit 400 newborns with a wide variety of possible genetic disorders, comparing whole genome sequencing to targeted genomic sequencing for accuracy and effectiveness. The researchers aim to determine if the targeted panel can be safely integrated into newborn care, eliminating ethical dilemmas and saving healthcare costs.
The collaboration aims to use clinical insights to fine-tune early device testing, focusing on preclinical support, proof of concept studies, de-risking medical device translation, and rapid prototyping. Tufts CTSI and MIT will provide resources and expertise to research teams to efficiently turn device concepts into testable prototypes.
The National Institutes of Health has awarded Tufts Clinical and Translational Science Institute (CTSI) $56 million to support its local, regional, and national research initiatives. The funding will accelerate the translation of research into clinical use, medical practice, and impact on health.
The JAX/Tufts CTSI collaboration aims to strengthen and expand research and training programs in clinical and translational science. Researchers will access Tufts CTSI resources for research design, clinical studies infrastructure, and fellowships.
Tufts Medical Center joins a new initiative to advance critical emergency medicine research with the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Network. The SIREN Network will conduct large-scale clinical trials to test new treatments in cardiology and neurology.
The two organizations will collaborate on activities in strategic mutual interest, supporting intellectual exchange of expert consulting. Researchers at Baim Institute contributed to the landmark IMMEDIATE Trial, which significantly reduced composite endpoint of cardiac arrest or mortality.
The JHU/Tufts MC/TUSM TIC will provide world-leading expertise in state-of-the-art trial design and execution of multi-site studies, particularly in neurology and cardiology. The center will lead innovative projects in clinical trial performance metrics and adaptive and integrated trial design to maximize trial performance.
A study found that investigators are more likely to respond to clinical trials if contacted by a point person or navigator. The Point-Person Project built a national network of navigators to find experts in pediatric clinical research.
A multidisciplinary research team has developed a new approach, E2E Clinical Trials, which aims to improve the accuracy of treatment selection by seamlessly transitioning from controlled efficacy trials to real-world effectiveness trials. This continuum will provide better understanding of treatment effects on diverse patient populations.
Tufts Medical Center has been awarded a PCORI funding award to develop a method for patient-centered enrollment in comparative effectiveness trials. The project, led by Dr. Harry P. Selker, will use data from electronic health records to identify patients who may benefit from clinical trials.
A team of researchers from the Tufts Clinical and Translational Science Institute emphasize the importance of translating biomedical research into real-world healthcare solutions. By likening the Affordable Care Act to traditional clinical trials, they highlight its potential to advance health care and wellness in the United States.
The Tufts Clinical and Translational Science Institute has received a $24 million grant from the National Institutes of Health to support its work over the next five years. The funding will accelerate the translation of laboratory research into clinical use, medical practice, and health policy.
A new book by Harry P. Selker, M.D., M.S.P.H., offers a fresh perspective on the Affordable Care Act, highlighting its potential as an experiment in translational research. The book explores the history, impact, and future of healthcare reform.
Researchers found that screening programs can save lives, but at a significant cost, with estimated annual costs ranging from $90,000 to $200,000 per life year saved. The study suggests that finite public health resources may be better spent elsewhere due to the rarity of conditions causing sudden cardiac death in children.